Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03593993 · ClinicalTrials.gov registry record
A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas
A clinical trial, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- 3
- Enrollment target
NCT03593993 is a clinical trial that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 3 participants.
The verdict
NCT03593993 was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors and may have efficacy in brain tumors with the BRAF V600E mutation.
Interventions
- PROCEDURE Surgical Cohort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-05-19 |
| Est. Completion | 2023-07-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03593993
The ClinicalTrials.gov registry entry for NCT03593993 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Surgical Cohort is the first listed.
NCT03593993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03593993 about?
NCT03593993 is a clinical study titled "A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas". This is a surgical biospecimen collection study. The purpose of this study is to understand how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn off the RAF signaling pathway. This is important because these drugs are currently FDA approved for other tumors a...
What is the current status of trial NCT03593993?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2018-05-19. Estimated completion is 2023-07-07.
What interventions are being tested in trial NCT03593993?
The interventions under investigation include: Surgical Cohort (PROCEDURE).
Who is sponsoring clinical trial NCT03593993?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.